Literature DB >> 10399068

Immunomodulation by viruses: the myxoma virus story.

P Nash1, J Barrett, J X Cao, S Hota-Mitchell, A S Lalani, H Everett, X M Xu, J Robichaud, S Hnatiuk, C Ainslie, B T Seet, G McFadden.   

Abstract

Myxoma virus is a poxvirus pathogen of rabbits that has evolved to replicate successfully in the presence of an active immune response by an infected host. To accomplish this, the virus has developed a variety of strategies to avoid detection by or obstruct specific aspects of the antiviral response whose consolidated action is antagonistic to virus survival. We describe two distinct viral strategies carried out by viral proteins with which myxoma virus subverts the host immune response. The first strategy is the production of virus-encoded proteins known as viroceptors or virokines that mimic host receptors or cytokines. These seek to actively block extracellular immune signals required for effective virus clearance and produce a local environment in the infected tissue that is "virus friendly". The second strategy, carried out by intracellular viral proteins, seeks to retard the innate antiviral responses such as apoptosis, and hinder attempts by the infected cell to communicate with the cellular arm of the immune system. By studying these viral strategies of immune evasion, the myxoma system can provide insights into virus-host interactions and also provide new insights into the complex immune system.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10399068     DOI: 10.1111/j.1600-065x.1999.tb01286.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  32 in total

1.  Harvesting viral proteins.

Authors:  A Lucas; G McFadden
Journal:  CMAJ       Date:  1999-11-02       Impact factor: 8.262

2.  CrmE, a novel soluble tumor necrosis factor receptor encoded by poxviruses.

Authors:  M Saraiva; A Alcami
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

3.  Poxvirus-induced immunostimulating effects on porcine leukocytes.

Authors:  V Fachinger; T Schlapp; W Strube; N Schmeer; A Saalmüller
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 4.  Poxvirus immunomodulatory strategies: current perspectives.

Authors:  J B Johnston; Grant McFadden
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

5.  Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death.

Authors:  Lisa M Sedger; Sarah R Osvath; Xiao-Ming Xu; Grace Li; Francis K-M Chan; John W Barrett; Grant McFadden
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

Review 6.  Viral Hormones: Expanding Dimensions in Endocrinology.

Authors:  Qian Huang; C Ronald Kahn; Emrah Altindis
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

7.  Post-translational modification of the myxoma-virus anti-inflammatory serpin SERP-1 by a virally encoded sialyltransferase.

Authors:  P Nash; M Barry; B T Seet; K Veugelers; S Hota; J Heger; C Hodgkinson; K Graham; R J Jackson; G McFadden
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

8.  Expression of secreted cytokine and chemokine inhibitors by ectromelia virus.

Authors:  V P Smith; A Alcami
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

9.  The viral anti-inflammatory chemokine-binding protein M-T7 reduces intimal hyperplasia after vascular injury.

Authors:  L Liu; A Lalani; E Dai; B Seet; C Macauley; R Singh; L Fan; G McFadden; A Lucas
Journal:  J Clin Invest       Date:  2000-06       Impact factor: 14.808

10.  Detection of myxoma viruses encoding a defective M135R gene from clinical cases of myxomatosis; possible implications for the role of the M135R protein as a virulence factor.

Authors:  Graham J Belsham; Charlotta Polacek; Solvej Ø Breum; Lars E Larsen; Anette Bøtner
Journal:  Virol J       Date:  2010-01-16       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.